Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas

Abstract

Background Few studies address the cost of treating prolactinomas. We performed a cost-utility analysis of surgical versus medical treatment for prolactinomas.

Materials and Methods We determined total hospital costs for surgically and medically treated prolactinoma patients. Decision-tree analysis was performed to determine which treatment produced the highest quality-adjusted life years (QALYs). Outcome data were derived from published studies.

Results Average total costs for surgical patients were $19,224 ( ± 18,920). Average cost for the first year of bromocriptine or cabergoline treatment was $3,935 and $6,042, with $2,622 and $4,729 for each additional treatment year. For a patient diagnosed with prolactinoma at 40 years of age, surgery has the lowest lifetime cost ($40,473), followed by bromocriptine ($41,601) and cabergoline ($70,696). Surgery also appears to generate high health state utility and thus more QALYs. In sensitivity analyses, surgery appears to be a cost-effective treatment option for prolactinomas across a range of ages, medical/surgical costs, and medical/surgical response rates, except when surgical cure rates are ≤ 30%.

Conclusion Our single institution analysis suggests that surgery may be a more cost-effective treatment for prolactinomas than medical management for a range of patient ages, costs, and response rates. Direct empirical comparison of QALYs for different treatment strategies is needed to confirm these findings.

Keywords

pituitary tumor - prolactinoma - cost - cost-effectiveness - cost-utility analysis - transsphenoidal surgery - dopamine agonist

• References

• 1 Colao A, Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol 2011; 7 (5) 267-278
• 2 Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27 (5) 485
• 3 Couldwell WT, Rovit RL, Weiss MH. Role of surgery in the treatment of microprolactinomas. Neurosurg Clin N Am 2003; 14 (1) 89-92 , vii
• 4 Liu JK, Couldwell WT. Contemporary management of prolactinomas. Neurosurg Focus 2004; 16 (4) E2
• 5 Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurg Clin N Am 2012; 23 (4) 669-678
• 6 Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006; 2 (10) 552-561
• 7 Sheplan Olsen LJ, Robles Irizarry L, Chao ST , et al. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary 2012; 15 (2) 135-145
• 8 Arduc A, Gokay F, Isik S , et al. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. J Endocrinol Invest 2015; 38 (4) 447-453
• 9 Anagnostis P, Adamidou F, Polyzos SA, Efstathiadou Z, Karathanassi E, Kita M. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience. Pituitary 2012; 15 (1) 25-29
• 10 Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JAH. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clin Endocrinol (Oxf) 2011; 75 (6) 819-824
• 11 Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95 (1) 43-51
• 12 Loyo-Varela M, Herrada-Pineda T, Revilla-Pacheco F, Manrique-Guzman S. Pituitary tumor surgery: review of 3004 cases. World Neurosurg 2013; 79 (2) 331-336
• 13 Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012; 15 (1) 71-83
• 14 Marko NF, LaSota E, Hamrahian AH, Weil RJ. Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg 2012; 117 (3) 522-538
• 15 Turner HE, Adams CB, Wass JA. Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?. Eur J Endocrinol 1999; 140 (1) 43-47
• 16 Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract 2001; 7 (3) 170-180
• 17 Zhen J-R, Yu Q, Zhang Y-H, Ma W-B, Lin S-Q. [Cost-effectiveness analysis of two therapeutic methods for prolactinoma]. Zhonghua Fu Chan Ke Za Zhi 2008; 43 (4) 257-261
• 18 Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK. Cost-effectiveness analysis of microscopic and endoscopic transsphenoidal surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg 2016; 87: 65-76
• 19 Husereau D, Drummond M, Petrou S , et al. Consolidated Health Economic Reporting Evaluation Standard (CHEERS) Statement. BMJ 2013; 346: 231-250
• 20 Centers for Disease Control and Prevention. FASTSTATS - Life expectancy. www.cdc.gov/nchs/fastats/life-expectancy.htm . Accessed September 13, 2016
• 21 Cesar de Oliveira Naliato E, Dutra Violante AH, Caldas D , et al. Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary 2008; 11 (3) 247-254
• 22 Ritvonen E, Karppinen A, Sintonen H , et al. Normal long-term health-related quality of life can be achieved in patients with functional pituitary adenomas having surgery as primary treatment. Clin Endocrinol (Oxf) 2015; 82 (3) 412-421
• 23 Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008; 11 (7) 1131-1143
• 24 Qu X, Wang M, Wang G , et al. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 2011; 164 (4) 499-504
• 25 Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins Jr LS. Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 2009; 12 (3) 158-164
• 26 Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999; 44 (2) 254-261 , discussion 261–263
• 27 Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF ; Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331 (14) 904-909
• 28 Kreutzer J, Buslei R, Wallaschofski H , et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 2008; 158 (1) 11-18
• 29 Hawthorne G, Richardson J, Day NA. A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Ann Med 2001; 33 (5) 358-370